Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Cytopenia 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 29fludarabine 19Rituximab 15fludarabine phosphate 12Specimen Handling 8obinutuzumab 7Immunotherapy, Adoptive 7Lenalidomide 6Etoposide 6pirtobrutinib 5ibrutinib 5glofitamab 5axicabtagene ciloleucel 5Whole-Body Irradiation 5Mycophenolic Acid 5venetoclax 4polatuzumab vedotin 4Prednisone 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Blood Component Removal 4Biopsy 4pembrolizumab 3daratumumab 3X-Rays 3Vincristine 3Stem Cell Transplantation 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Non-Hodgkin × Emapalumab × Clear all
NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡